Why Crohn's disease trial monitoring matters
Inflammatory bowel disease — particularly Crohn's disease — is one of the most active therapeutic areas in immunology. The IBD pipeline has expanded dramatically with the validation of new targets like TL1A, the maturation of selective IL-23 inhibitors, and the emergence of oral small molecule approaches including JAK inhibitors and S1P receptor modulators.
For pharma BD teams, biotech investors, and gastroenterology researchers, the pace of IBD clinical development creates a significant monitoring challenge. Key signals to track:
- Anti-TL1A programs — the most competitive new target class in IBD following tulisokibart and duvakitug
- Selective IL-23 inhibitors (risankizumab, guselkumab, mirikizumab competitors)
- JAK inhibitor programs (selective JAK1, TYK2 inhibitors) addressing safety profile optimization
- S1P receptor modulators expanding from ulcerative colitis to Crohn's disease
- Combination therapy trials — biologics + small molecules, dual-mechanism approaches
- Biomarker-driven patient selection trials advancing precision medicine in IBD
- Pediatric Crohn's disease trials — a growing area of unmet need
Get daily Crohn's disease trial digest
Set your profile once. Receive a clean digest every morning with new trials and updates matching your criteria.
Get the Free DigestWhat we monitor for Crohn's disease
Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a Crohn's/IBD watch profile, you can configure:
- Condition keywords: "Crohn's disease", "Crohn disease", "inflammatory bowel disease", "IBD", "fistulizing Crohn's", "pediatric Crohn's"
- Phase filter: Phase 1 only, Phase 2/3, or all phases
- Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
- Status filter: Recruiting only, all active studies, or any status
The Crohn's disease treatment landscape in 2026
Anti-TL1A antibodies — the next blockbuster target
TL1A (TNF-like ligand 1A) has emerged as the most validated new target in IBD since anti-TNF therapy. Multiple programs from major pharma companies are racing through clinical development, with tulisokibart (Merck) and duvakitug (AbbVie/Teva) leading the way. Monitoring new TL1A trial registrations provides early competitive intelligence on this rapidly evolving space.
Next-generation IL-23 inhibition
Following the success of risankizumab (Skyrizi) in Crohn's disease, the IL-23 class is expanding with multiple agents in development. Competitive dynamics are intensifying as companies differentiate on dosing convenience, combination strategies, and head-to-head trial designs.
Oral small molecules
JAK inhibitors and S1P receptor modulators offer the appeal of oral dosing in a market dominated by injectable biologics. The challenge has been balancing efficacy with safety, and new-generation selective inhibitors aim to improve the therapeutic index. Tracking oral agent trials is essential for understanding the future competitive landscape.
Combination and sequencing trials
The IBD field is increasingly exploring combination approaches — pairing biologics with small molecules, or using sequential therapy strategies. These trials represent the frontier of Crohn's disease treatment and often signal where the field is headed.
Who uses Crohn's disease trial monitoring
Pharma immunology teams
Companies with IBD portfolios track competitor trial activity to inform development strategy, partnership decisions, and market access planning. A new Phase 3 program in moderate-to-severe Crohn's disease represents a future competitive entry that affects commercial planning.
Biotech investors
IBD has become one of the highest-value therapeutic markets globally. Investors track trial starts and phase transitions to identify catalysts, de-risk pipeline bets, and understand competitive positioning.
Gastroenterology researchers
Academic gastroenterologists and IBD researchers monitor new trial registrations to identify collaboration opportunities, refer patients to appropriate clinical trials, and stay current on emerging treatment approaches.
Patient advocacy organizations
Organizations like the Crohn's & Colitis Foundation track recruiting trials to help patients access new treatment options through clinical trial participation.
Ready to automate your Crohn's disease trial monitoring?
free plan — no credit card required.
Start FreeFrequently asked questions
How current is the Crohn's disease trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track Crohn's disease and ulcerative colitis together?
Yes. You can create a broader "IBD" profile that covers both Crohn's disease and ulcerative colitis, or separate profiles for each. On the Pro plan ($149/month), you can create unlimited watchlists.
Does this cover international IBD trials?
ClinicalTrials.gov includes trials conducted internationally, so yes — international Crohn's disease trials registered on ClinicalTrials.gov are included.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Crohn's Disease trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial quietly adding a dozen new sites does not read the same as a contact-details edit.
488 active trials, 302 recruiting.
Industry sponsors run 115 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 46.
| Top industry sponsor | Active trials |
|---|---|
| Johnson & Johnson / Janssen | 21 |
| AbbVie | 16 |
| Takeda | 16 |
| Eli Lilly and Company | 7 |
| Sanofi / Regeneron | 5 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's… NCT06581328 | Recruiting | Primary completion moved earlier: 2027-10-01 → 2027-05-01 | 2026-09-16 |
| Adapted Physical Activity for Persistent Fatigue in Patients With Inflammatory… NCT07804511 | Not Yet Recruiting | Primary endpoint(s) modified | 2026-09-12 |
| IBD Strong Peer2Peer for Self-Management of Psychological Distress NCT05722236 | Recruiting | Completion pushed: 2026-03 → 2027-03 | 2026-09-10 |
| A Mindfulness-based Stress Reduction Program for IBD NCT07266883 | Not Yet Recruiting | Completion pushed: 2027-02-01 → 2028-02-01 | 2026-09-09 |
| LMT503 First-in-human SAD, MAD, and FE Study NCT05659953 | Not Yet Recruiting | Completion pushed: 2026-03-01 → 2027-12-01 | 2026-09-02 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.